Go or no go? Vaccines and neurology up for discussion

Several FDA advisory committee hearings are set for March, including one for GSK’s adult respiratory syncytial virus (RSV) vaccine Arexvy, following today’s panel on Pfizer’s rival candidate. Both jabs are expected to get positive recommendations. Biogen’s ALS project tofersen will also come in front of an adcom later in the month to determine whether it warrants accelerated approval.